In 2011, the first BRAF-V600E targeted inhibitor, Vemurafenib (41, Figure 8), was approved by the FDA for the treatment of patients with BRAF-V600E mutations in advanced melanoma and achieved breakthrough therapeutic effects (Bollag et al., 2012). The gene discussed is BRAF; the disease is melanoma.